Beijing: Recent studies have revealed that the diabetes medication liraglutide can slow the progression of Alzheimer’s disease.
Liraglutide, a drug developed by Novo Nordisk, is known for its use in treating diabetes and obesity.
However, recent research suggests that liraglutide may also protect the brain and slow the advancement of Alzheimer’s disease.
This medication, marketed under the brand names Victoza for diabetes and Saxenda for obesity, has shown potential health benefits beyond weight loss and blood sugar management.
Recent studies have increased demand for GLP-1 medications, and experts are exploring the potential of Novo Nordisk’s liraglutide in treating chronic conditions ranging from liver disease to sleep disorders.